Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT06906081

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06906081
  • EU CT 2024-516597-30-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06906081. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-02 (actual); primary completion 2028-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study
Acronym
FibroCAN
Condition
Cardiovascular Autonomic Neuropathy
Condition
Diabetic Neuropathies
Intervention (Drug)
Kerendia (Finerenone, BAY94-8862)
Intervention (Drug)
Placebo
Lead sponsor
Peter Rossing (class: other)
Collaborator
Steno Diabetes Center Nordjylland (class: other)
Collaborator
Aarhus University Hospital (class: other)

Record details

Record id
cardio:ct-nct06906081
Content hash
7f7eca9eef0c07ecb63858ce810cac6f615940ccc33409b96a457788cc0d9328